On September 8, during intraday trading, the pharmaceutical sector was under overall pressure, but Eli Lilly (Lilly) showed resilience. Meanwhile, the delivery data Boeing released was a mixed bag—part positive, part negative. These developments may seem isolated, but they could be influencing your holdings through two clues: interest-rate expectations and the industry cycle.

First, a broad selloff in pharmaceutical stocks is often related to warming interest-rate expectations, because higher rates reduce the present value of future cash flows for innovative drug companies. However, Lilly’s ability to hold up against the trend may stem from market confidence in its obesity-drug pipeline; demand for this kind of product tends to be relatively rigid and less sensitive to interest rates. If the Federal Reserve issues even more hawkish signals later on, sector differentiation could intensify.

Looking at Boeing again, mixed delivery data means commercial aircraft deliveries may improve, but a drag from defense or space business could weigh on the overall picture. This is directly tied to the supply chain and the state of manufacturing activity. If delivery improvement is a trend, it would be favorable for the aviation industry chain, but you should still be wary of geopolitical risks in the defense business.

There is limited market data right now, but what can be observed is this: if the S&P 500 index holds key moving averages after today’s fluctuations, then risk appetite hasn’t collapsed; meanwhile, if the yield on 10-year U.S. Treasuries breaks above the prior high, it will strengthen the interest-rate narrative and pressure high-valued growth stocks.

Next, you should track whether Eli Lilly can continue to outperform the sector across subsequent trading days, and whether the proportion of defense versus commercial in Boeing’s monthly delivery breakdown changes. If a Fed official unexpectedly turns dovish, or if Boeing’s defense orders rebound sharply, then the above logic needs to be revised.

Risk warning: This article is for information interpretation only and does not constitute investment advice.